Agree with you, @Phaedrus, that the company was juggling too many balls or dealing with too much uncertainty in December. I don’t like the level at which the CR was done, but people also don’t seem to realise or remember how much of a massive as well as crucial turnaround the company went through in the first quarter, in so many different ways. Could there have been less dilution? Perhaps, but I personally believe that the company might have been on its knees without the cap raise, in which case the “adaptation” of the FDA would have been completely futile. Instead, in a quick succession of moves, it got the ship righted.
Hand on heart, as a top 500 shareholder I can say I have applauded the management team’s moves in the last few months.
Agree with you, @Phaedrus, that the company was juggling too...
-
- There are more pages in this discussion • 226 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.8¢ |
Change
-0.003(0.25%) |
Mkt cap ! $1.138B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.01 | 98.0¢ | $4.344M | 4.367M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 93.5¢ | 22283 | 5 |
View Market Depth
| Last trade - 15.59pm 25/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |